http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019210866-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d94573ab2c57e8b193f3a22accddf9fe |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4409 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4409 |
| filingDate | 2019-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4877e0597dc43a16599fd601e6e8b7cb |
| publicationDate | 2019-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2019210866-A1 |
| titleOfInvention | Use of sphk2 inhibitor as drug for repairing bone marrow hematopoietic system injury or treating bone marrow hematopoietic dysfunction |
| abstract | Disclosed are a use of an SPHK2 inhibitor in the preparation of a drug for treating the diseases hematopoietic dysfunction, hematopoietic stem cell damage, complete blood count decrease, or immune cell reduction, for improving hematopoietic stem cell self-renewal and hematopoietic function, or for promoting rehabilitation after a bone marrow transplant, and a use of the SPHK2 gene or protein in screening a drug for treating hematopoietic stem cell injury. ABC294640 increases the number and function of hematopoietic stem cells, and also enhances the ability of hematopoietic stem cells to differentiate into a variety of blood cells and blood immune cells, helping patients quickly pass through the period of being on the verge of death after a transplant. ABC294640 can also be used to treat primary hematopoietic dysfunction or symptoms of hematopoietic dysfunction caused by radiation and chemical drug stimulation, and can enhance the recovery of the hematopoietic function of and prolong the survival of patients after multiple instances of chemotherapy by improving hematopoietic stem cell function. The SPHK2 inhibitor provides a new drug source for the treatment of primary or induced hematopoietic dysfunction and for the treatment of the complications of various types of hematopoietic dysfunction in bone marrow transplant patients. |
| priorityDate | 2018-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.